Maintenance therapy for CTCL: importance for prevention of disease progression.

IF 2.2 4区 医学 Q3 HEMATOLOGY
Emily R Gordon, Megan H Trager, Bradley D Kwinta, Connor J Stonesifer, Kaitlyn J Lee, Oluwaseyi Adeuyan, Brigit A Lapolla, Oleg E Akilov, Paula A Enz, Emmanuella Guenova, Pablo L Ortiz-Romero, Evangelia Papadavid, Pietro Quaglino, Sima Rozati, Julia J Scarisbrick, Thomas Litman, Larisa J Geskin
{"title":"Maintenance therapy for CTCL: importance for prevention of disease progression.","authors":"Emily R Gordon, Megan H Trager, Bradley D Kwinta, Connor J Stonesifer, Kaitlyn J Lee, Oluwaseyi Adeuyan, Brigit A Lapolla, Oleg E Akilov, Paula A Enz, Emmanuella Guenova, Pablo L Ortiz-Romero, Evangelia Papadavid, Pietro Quaglino, Sima Rozati, Julia J Scarisbrick, Thomas Litman, Larisa J Geskin","doi":"10.1080/10428194.2024.2376164","DOIUrl":null,"url":null,"abstract":"<p><p>There are no established maintenance protocols for cutaneous lymphomas. We aim to determine patient treatments and outcomes during the COVID-19 pandemic in order to uncover the most effective maintenance protocols for cutaneous lymphomas and impact of treatment interruption. Data was collected retrospectively from nine international institutions, including 149 patients. Younger patients had earlier stages of disease and were most frequently treated with skin-directed therapies including topical steroids, mechlorethamine gel, and phototherapy. Treatment interruption varied by treatment type and stage, with patients on topical therapies and earlier stages of disease being least likely to experience interruption. Treatment interruption was significantly associated with progression of disease and worse outcomes, with twice as many patients progressing who had interruption compared to those without interruption. This study may demonstrate the significance of continuous maintenance therapies, even in younger patients with early stages of disease.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2024.2376164","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

There are no established maintenance protocols for cutaneous lymphomas. We aim to determine patient treatments and outcomes during the COVID-19 pandemic in order to uncover the most effective maintenance protocols for cutaneous lymphomas and impact of treatment interruption. Data was collected retrospectively from nine international institutions, including 149 patients. Younger patients had earlier stages of disease and were most frequently treated with skin-directed therapies including topical steroids, mechlorethamine gel, and phototherapy. Treatment interruption varied by treatment type and stage, with patients on topical therapies and earlier stages of disease being least likely to experience interruption. Treatment interruption was significantly associated with progression of disease and worse outcomes, with twice as many patients progressing who had interruption compared to those without interruption. This study may demonstrate the significance of continuous maintenance therapies, even in younger patients with early stages of disease.

CTCL 的维持治疗:预防疾病恶化的重要性。
目前还没有针对皮肤淋巴瘤的成熟的维持治疗方案。我们的目的是确定 COVID-19 大流行期间患者的治疗方法和结果,从而发现最有效的皮肤淋巴瘤维持治疗方案以及治疗中断的影响。我们从九个国际机构回顾性收集了数据,其中包括 149 名患者。年轻患者的病程较早,最常采用皮肤导向疗法,包括局部类固醇、甲氯雷他敏凝胶和光疗。治疗中断的情况因治疗类型和阶段而异,使用局部疗法和病程较早的患者最不可能中断治疗。治疗中断与病情恶化和预后恶化密切相关,中断治疗的患者病情恶化的比例是未中断治疗患者的两倍。这项研究可能证明了持续维持疗法的重要性,即使是对年轻的早期患者也是如此。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Leukemia & Lymphoma
Leukemia & Lymphoma 医学-血液学
CiteScore
4.10
自引率
3.80%
发文量
384
审稿时长
1.8 months
期刊介绍: Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信